Table 1.

Common cytogenetic subtypes of B-cell precursor ALL and AML: the NCCLS, 1995–2008

B-cell precursor ALL (n = 701a)AML (n = 138b)
N (%)cN (%)c
No apparent abnormality73 (10.4)No apparent abnormality25 (18.1)
Total structural changes397 (56.6)Total structural changes103 (74.6)
 Translocation t(12;21)143 (20.4) Translocation t(8;21)21 (15.2)
 Translocations other than t(12;21)87 (12.4) Translocation t(15;17)14 (10.1)
  t(1;19)23 (3.3) Inversion inv(16)7 (5.1)
  t(9;22)8 (1.1)
  11q23/MLL rearrangement22 (3.1) 11q23/MLL rearrangement17 (12.3)
 Any deletion75 (10.7) Any deletion21 (15.2)
  del(12p)36 (5.1)  del(9q)5 (3.6)
  del(6q)17 (2.4)
  del(9p)17 (2.4)
Total numerical changes413 (58.9)Total numerical changes55 (39.9)
 Trisomy 852 (7.4) Trisomy 818 (13.0)
 Monosomy 718 (2.6)
Ploidy level
 High hyperdiploidy (51–67 chr.)237 (33.8)
 Low hyperdiploidy (47–50 chr.)112 (16.0) Low hyperdiploidy (47–50 chr.)31 (22.5)
 Hypodiploidy (45 chr.)28 (4.0) Hypodiploidy (45 chr.)9 (6.5)
 Pseudodiploid183 (26.1) Pseudodiploid71 (51.4)

Abbreviation: chr., chromosome.

  • aIncludes 145 cases in phase I (1995–1999) and 556 cases in phase II (2000–2008).

  • bIncludes 39 cases in phase I (1995–1999) and 99 cases in phase II (2000–2008).

  • cLeukemia case may have more than one chromosome abnormality.